Upadacitinib improves symptoms of concomitant allergic rhinitis or allergic asthma in patients with severe atopic dermatitis: A 16‐week multicentre retrospective study

• DOI: 10.1111/jdv.19862
• Publication Date: 2024-02-08T13:10:17Z
• Authors: L. Gargiulo; L. Ibba; F. Piscazzi; F. Amoruso; A. Balato; F. Barei; M. Bertello; A. G. Burroni; S. Caccavale; S. M. Ferrucci; C. Foti; F. M. Gaiani; G. Girolomoni; P. Malagoli; A. V. Marzano; M. Maurelli; M. Napolitano; E. Nettis; M. Ortoncelli; C. Patruno; E. Pezzolo; S. Ribero; P. Romita; M. T. Rossi; I. Zaza; M. B. Guanti; A. Costanzo; A. Narcisi
• Keywords: Male; Adult; Humans; Female; Middle Aged; Atopic dermatitis, Upadacitinib allergic rhinitis, allergic asthma; Heterocyclic Compounds, 3-Ring; Rhinitis, Allergic; Severity of Illness Index; Asthma; Retrospective Studies; Dermatitis, Atopic

Atopic dermatitis (AD) is the most common inflammatory skin disease often associated with comorbidities, including allergic rhinitis (AR; 40.3% of patients) and allergic asthma (AA; 51.3%).1 Among systemic treatments approved for severe AD, dupilumab is also indicated for the treatment of chronic rhinosinusitis with nasal polyps, AA and eosinophilic esophagitis.2,3 Upadacitinib, a selective JAK1-inhibitor approved for severe AD, lacks approval for AA and AR.4–6 We retrospectively analysed data from 11 Italian dermatology units to determine whether upadacitinib could improve symptoms related to AA or AR in patients with severe AD.